Kerri Fitzgerald

DocwireNews

The risk of serious infections, opportunistic infections, and cancer is increased in patients with rheumatologic diseases who take interleukin (IL) inhibitors, according to a study published in JAMA Network Open.Researchers conducted a literature review of randomized, controlled trials published through November 2018 that evaluated IL inhibitor therapies in rheumatic diseases and reported on safety.The researchers selected 74 studies that included 29,214 patients. The following drugs were included: anakinra (IL-1), rilonacept (IL-1), canakinumab (IL-1), tocilizumab (IL-6), olokizumab (IL-6), clazakizumab (IL-6), sirukumab (IL-6), sarilumab (IL-6), ustekinumab (IL-12/23), <a href="https://www.docwirenews.com/docwire-pick/il-17-pathway-in-the-pathogenesis-of-spondyloarthritis/">brodalumab (IL-17)</a>, secukinumab (IL-17), ixekizumab (IL-17), and guselkumab (IL-23).<h2>Increased risk of infection, cancer with IL treatment</h2>There were 486 events in the treatment arms and 96 events in the placebo arms. Among this patient cohort, 24,236 had serious infections, 9,998 had opportunistic infections, and 21,065 had cancer (the number of patients overlaps for each outcome).Patients receiving IL inhibitors had a higher risk of serious infections (odds ratio [OR] = 1.97; 95% CI, 1.58-2.44;&nbsp;P&lt;0.001), opportunistic infections (OR=2.35; 95% CI, 1.09-5.05;&nbsp;P=0.03), and cancer (OR=1.52; 95% CI, 1.05-2.19;&nbsp;P=0.03).&ldquo;The findings in our study suggest that the risk of cancer may be increased with longer IL inhibitor therapy,&rdquo; the authors wrote.The results &ldquo;should be taken into consideration and needs to be confirmed by real-world data, such as long-term epidemiologic studies from registries,&rdquo; according to the researchers.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Interleukin Inhibitors Increase Infection, Cancer Risk for Patients With Rheumatologic Diseases

Oncology

The risk of serious infections, opportunistic infections, and cancer is increased in patients with rheumatologic diseases who take interleukin (IL) inhibitors, according to a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe